Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Antibody Fragments Market?

In recent past, there has been significant growth in the market size of antibody fragments. The market which stands at $10.35 billion in 2024, is predicted to propel to $11.26 billion in 2025, witnessing a compound annual growth rate (CAGR) of 8.8%. The accelerated growth rate in the past years is a result of surge in chronic diseases, rising acceptance of biologics, increase in cancer treatment options, regulatory clearance for antibody-based therapies, and the broadening of biopharmaceutical research.

The market size for antibody fragments is predicted to witness robust expansion in the upcoming years, escalating to $16.08 billion in 2029 with a compound annual growth rate (CAGR) of 9.3%. Several factors contributing to this growth projection are an increase in research and development expenditures in biologics, a growing inclination towards more compact antibody formats, and a thriving demand for personalized medicine. Additionally, expansive applications in autoimmune diseases and the emergence of bispecific antibodies also supplement market growth. Noteworthy trends for the forecast period encompass integration with AI-enabled drug discovery, the creation of cost-efficient production techniques, partnerships among biotech corporations, advances in monoclonal antibody technology, and a concentrated focus on antibody-drug conjugates.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23307&type=smp

What Growth-Enabling Forces Are Impacting The Antibody Fragments Market?

The rise in the occurrence of specific diseases is anticipated to drive the growth of the antibody fragments market. These specific diseases, also known as target diseases, are particular health conditions or illnesses that a medical treatment, medication, or research aims to manage, prevent, or cure. Key target diseases encompass cancer, bacterial infections, and infectious diseases. This rise is predominantly attributed to unhealthy habits and pollution, which impair the body’s immune system, leading to chronic diseases. Antibody fragments offer highly precise, versatile, and targeted alternatives for treating a wide range of diseases, often minimizing side effects compared to traditional therapies. Their ability to be tailored and designed for specific targets makes them an indispensable resource in contemporary medicine. For example, a report released by the American Cancer Society, a non-profit organization in the US, in January 2025 indicates that the US is estimated to record 2,041,910 fresh cancer cases and 618,120 cancer mortalities in 2025, a hike from 2,001,140 new cases and 611,720 deaths in 2024. Therefore, the escalating occurrence of target diseases is promoting the growth of the antibody fragments market.

What Are The Key Segment Trends Observed In The Antibody Fragments Market?

The antibody fragments market covered in this report is segmented –

1) By Type: F(ab) Fragments, F(ab’)2 Fragments, Single-Chain Variable Fragments (scFvs), Single Domain Antibody Fragments (sdAbs), Other Types

2) By Specificity: Monoclonal Antibody, Polyclonal Antibody

3) By Delivery Method: Intravenous (IV), Subcutaneous (SC), Oral, Transdermal

4) By Application: Cancer, Immunodeficiencies, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Diagnostic Laboratories, Contract Research Organizations (CROs)

Subsegments:

1) By F(ab) Fragments: Recombinant F(ab) Fragments, Enzymatically Derived F(ab) Fragments

2) By F(ab’)2 Fragments: Pepsin-Derived F(ab’)2 Fragments, Recombinant F(ab’)2 Fragments

3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs), Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs), Yeast-Produced Single-Chain Variable Fragments (scFvs)

4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs), Shark-Derived Single Domain Antibody Fragments (sdAbs), Synthetic Single Domain Antibody Fragments (sdAbs)

5) By Other Types: Bispecific Antibody Fragments, Multispecific Antibody Fragments, Fusion Protein Antibody Fragments

Which Disruptive Trends Are Driving Change Across The Antibody Fragments Market?

Leading firms in the antibody fragments market are prioritizing clinical trials to create advance products like human VH antibody fragments, aimed at improving the effectiveness of targeted therapies and minimizing immunogenicity in the treatment of cancers, autoimmune conditions, and infectious diseases. The human VH antibody fragment is the variable section of the human antibody’s heavy chain, with the ability to independently bind antigens. This component is fundamental in forming antibody fragments as it is the critical antigen-binding area. It is typically employed on its own or in conjunction with other molecules to develop compact, stable, and high-affinity therapeutic or diagnostic antibodies. In May 2024, for example, Zai Lab Limited, a pharmaceutical company based in China, started a global Phase 2 clinical trial to assess the safety and efficiency of ZL-1102. This innovative human VH antibody fragment (Humabody) targets IL-17 and is under development as a topical therapy for mild to moderate chronic plaque psoriasis to enhance treatment accuracy while lowering systemic side effects and immunogenic reactions.

Who Are The Major Stakeholders Operating In The Antibody Fragments Market?

Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antibody-fragments-global-market-report

What Regional Factors Are Accelerating Growth In The Antibody Fragments Market?

North America was the largest region in the antibody fragments market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody fragments market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23307&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model